Neuphoria Therapeutics
NEUP
11 hedge funds and large institutions have $6.52M invested in Neuphoria Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
1,033% more capital invested
Capital invested by funds: $575K → $6.52M (+$5.94M)
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
267% more funds holding
Funds holding: 3 → 11 (+8)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.46M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.26M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$962K |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$302K |
| 5 |
VF
Virtu Financial
New York
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$120K |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$60.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
1
Lynx1 Capital Management
San Juan,
Puerto Rico
| $2.2M | +$1.46M | +67,959 | New |
|
|
TCM
2
Tang Capital Management
San Diego,
California
| $1.89M | +$1.26M | +58,333 | New |
|
|
3
Point72 Asset Management
Stamford,
Connecticut
| $1.79M | +$962K | +44,636 | +425% |
|
|
OCA
4
Octagon Capital Advisors
New York
| $454K | +$302K | +14,000 | New |
|
|
BI
5
BVF Inc
San Francisco,
California
| $128K | -$60.4K | -2,800 | -41% |
|
|
VF
6
Virtu Financial
New York
| $45K | +$29.7K | +1,380 | New |
|
7
UBS Group
Zurich,
Switzerland
| $6.7K | +$4.46K | +207 | New |
|
|
FIA
8
FNY Investment Advisers
New York
| $5K | +$3.81K | +177 | New |
|
9
RhumbLine Advisers
Boston,
Massachusetts
| $1.36K | +$905 | +42 | New |
|
|
APC
10
Aspire Private Capital
Cornelius,
North Carolina
| $540 | +$366 | +17 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $146 | +$108 | +5 | New |
|
|
WP
12
Woodline Partners
San Francisco,
California
| – | -$120K | -4,537 | Closed |
|
NEUP Hedge Fund Activity: Q3 2023 in Review
11 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q3 2023, worth a combined $6.52M — up 1,033% from $575K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NEUP positions and 1 closed out — a net gain of 8 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $1.46M. The largest seller was Woodline Partners, exiting entirely with an estimated $120K sold.
- 11 institutional investors held Neuphoria Therapeutics (NEUP) as of Q3 2023, up from 3 in Q2 2023.
- Funds reported $6.52M of Neuphoria Therapeutics stock for Q3 2023, up 1,033% quarter-over-quarter.
- 9 funds opened new Neuphoria Therapeutics positions in Q3 2023 and 1 closed out, a net change of +8 holders.
- The largest Neuphoria Therapeutics buyer in Q3 2023 was Lynx1 Capital Management, an estimated $1.46M added.
- The largest Neuphoria Therapeutics seller in Q3 2023 was Woodline Partners, an estimated $120K sold.
Based on aggregated 13F filings for Q3 2023.